Cullen Frost Bankers Inc. Purchases 1,075 Shares of Eli Lilly and Company $LLY

Cullen Frost Bankers Inc. increased its position in Eli Lilly and Company (NYSE:LLY) by 1.0% during the 2nd quarter, Holdings Channel reports. The firm owned 103,839 shares of the company’s stock after acquiring an additional 1,075 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Cullen Frost Bankers Inc.’s investment portfolio, making the stock its 25th largest holding. Cullen Frost Bankers Inc.’s holdings in Eli Lilly and Company were worth $80,946,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Precedent Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its position in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $54,000. Duquesne Family Office LLC grew its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares during the period. Finally, Corient IA LLC acquired a new stake in Eli Lilly and Company in the 1st quarter worth about $570,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LLY. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Finally, BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Stock Down 1.1%

LLY stock opened at $799.85 on Wednesday. The firm has a market cap of $757.03 billion, a PE ratio of 52.28, a PEG ratio of 1.16 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s 50 day moving average price is $759.77 and its 200-day moving average price is $766.43. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald bought 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jamere Jackson bought 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.